Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]
Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
This is a single-center, phase 2 randomized clinical trial of tamoxifen on mean percent
predicted isometric muscle strength in patients with amyotrophic lateral sclerosis (ALS). The
purpose is to determine whether the triphenylethylenetamoxifen, used as adjuvant therapy in
the treatment of breast cancer, can delay the loss of isometric muscle strength in ALS
patients.